Suppr超能文献

错配修复缺陷型子宫内膜癌中共享新抗原图谱的特征分析

Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer.

作者信息

De Paolis Elisa, Nero Camilla, Micarelli Elisa, Leoni Guido, Piermattei Alessia, Trozzi Rita, Scarselli Elisa, D'Alise Anna Morena, Giacò Luciano, De Bonis Maria, Preziosi Alessia, Daniele Gennaro, Piana Diletta, Pasciuto Tina, Zannoni Gianfranco, Minucci Angelo, Scambia Giovanni, Urbani Andrea, Fanfani Francesco

机构信息

Departmental Unit of Molecular and Genomic Diagnostics, Genomics Research Core Facility, Gemelli Science and Technology Park (GSTeP), Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Clinical Chemistry, Biochemistry and Molecular Biology Operations (UOC), Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

出版信息

NPJ Precis Oncol. 2024 Dec 20;8(1):283. doi: 10.1038/s41698-024-00779-4.

Abstract

Endometrial cancer (EC) with Mismatch Repair deficiency (MMRd) is characterized by the accumulation of insertions/deletions at microsatellite sites. These mutations lead to the synthesis of frameshift peptides (FSPs) that represent tumor-specific neoantigens (nAg) proved to be shared across patients/tumors with MMRd. In this study, we explored the feasibility of a nAg-based cancer vaccination design in EC with MMRd. We adopted a whole exome sequencing approach and ad hoc bioinformatics pipelines to characterize FSPs in 35 patients with EC. A mean of 146 mutated mononucleotide repeats (MNRs) was identified with enrichment in the patients' group with MLH1 impairment. A high coverage emerged from the comparative analysis of the EC FSPs with the content of the previously validated NOUS-209 vaccine. We obtained pieces of evidence of FSPs translation as expressed proteins from Ribo-seq, supporting the potential as the target of vaccination. The development of a nAgs-based vaccine strategy in MMRd EC may be further explored.

摘要

错配修复缺陷(MMRd)的子宫内膜癌(EC)的特征是微卫星位点插入/缺失的积累。这些突变导致移码肽(FSP)的合成,这些移码肽代表肿瘤特异性新抗原(nAg),已被证明在患有MMRd的患者/肿瘤中是共享的。在本研究中,我们探讨了基于nAg的癌症疫苗设计在MMRd的EC中的可行性。我们采用了全外显子组测序方法和专门的生物信息学管道来表征35例EC患者中的FSP。平均鉴定出146个突变的单核苷酸重复序列(MNR),在MLH1受损的患者组中富集。通过将EC FSP与先前验证的NOUS-209疫苗的内容进行比较分析,发现了高覆盖率。我们从核糖体测序(Ribo-seq)中获得了FSP作为表达蛋白翻译的证据,支持了其作为疫苗靶点的潜力。在MMRd的EC中基于nAg的疫苗策略的开发可能需要进一步探索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df4d/11662070/a40064792695/41698_2024_779_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验